Evidence map›Paper›PMID 31334547›Full record

ArticleHuman molecular genetics2019

Underlying molecular alterations in human dihydrolipoamide dehydrogenase deficiency revealed by structural analyses of disease-causing enzyme variants.

Eszter Szabo, Piotr Wilk, Balint Nagy, Zsofia Zambo, David Bui, Andrzej Weichsel, Palaniappa Arjunan, Beata Torocsik, Agnes Hubert, William Furey and 5 more

Open access · greenAbstract read
In one paragraph

Article in Human molecular genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Eszter SzaboDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Piotr WilkMacromolecular Crystallography, Helmholtz-Zentrum Berlin, 12489, Berlin, Germany.
Balint NagyDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Zsofia ZamboDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
David BuiDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Andrzej WeichselDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, USA.
Palaniappa ArjunanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15261, USA.
Beata TorocsikDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Agnes HubertDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
William FureyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15261, USA.
William R MontfortDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, 85721, USA.
Frank JordanDepartment of Chemistry, Rutgers, The State University of New Jersey, Newark, NJ, 07102, USA.
Manfred S WeissMacromolecular Crystallography, Helmholtz-Zentrum Berlin, 12489, Berlin, Germany.
Vera Adam-ViziDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Attila AmbrusDepartment of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, Budapest, 1094, Hungary.
Semmelweis University · HUHelmholtz-Zentrum Berlin für Materialien und Energie · DEUniversity of Arizona · USUniversity of Pittsburgh · USRutgers, The State University of New Jersey · US

Funding

STRUCTURE AND MECHANISM OF YEAST PYRUVATE DECARBOXYLASER01GM050380 · NIGMS · RUTGERS THE STATE UNIV OF NJ NEWARK · PI JORDAN, FRANK · 1993 to 2013
$3.0M
Nitric Oxide Signaling in Health and DiseaseR01GM117357 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2015 to 2018
$1.4M
Pyruvate Dehydrogenase Assembly, Structure & FunctionR01GM121469 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FUREY, WILLIAM F · 2017 to 2020
$1.2M
Mechanistic Issues Related to Aging on Human 2-Oxoglutarate Dehydrogenase ComplexR15GM116077 · NIGMS · RUTGERS THE STATE UNIV OF NJ NEWARK · PI JORDAN, FRANK · 2015 to 2015
$369k
NIGMS NIH HHS R01 GM050380NIGMS NIH HHS R01 GM117357NIGMS NIH HHS R01 GM121469NIGMS NIH HHS R15 GM116077
6 · The paper itself

Abstract

Human dihydrolipoamide dehydrogenase (hLADH, hE3) deficiency (OMIM# 246900) is an often prematurely lethal genetic disease usually caused by inactive or partially inactive hE3 variants. Here we report the crystal structure of wild-type hE3 at an unprecedented high resolution of 1.75 Å and the structures of six disease-causing hE3 variants at resolutions ranging from 1.44 to 2.34 Å. P453L proved to be the most deleterious substitution in structure as aberrations extensively compromised the active site. The most prevalent G194C-hE3 variant primarily exhibited structural alterations close to the substitution site, whereas the nearby cofactor-binding residues were left unperturbed. The G426E substitution mainly interfered with the local charge distribution introducing dynamics to the substitution site in the dimer interface; G194C and G426E both led to minor structural changes. The R460G, R447G and I445M substitutions all perturbed a solvent accessible channel, the so-called H+/H2O channel, leading to the active site. Molecular pathomechanisms of enhanced reactive oxygen species (ROS) generation and impaired binding to multienzyme complexes were also addressed according to the structural data for the relevant mutations. In summary, we present here for the first time a comprehensive study that links three-dimensional structures of disease-causing hE3 variants to residual hLADH activities, altered capacities for ROS generation, compromised affinities for multienzyme complexes and eventually clinical symptoms. Our results may serve as useful starting points for future therapeutic intervention approaches.

Indexed as

Catalytic DomainDihydrolipoamide DehydrogenaseHumansMultienzyme ComplexesMutagenesis, Site-DirectedMutationProtein ConformationReactive Oxygen SpeciesDihydrolipoamide DehydrogenaseMultienzyme ComplexesReactive Oxygen Species

Identifiers

PMID31334547
PMCPMC7275779
OpenAlexW2964112116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.